The Zhitong Finance App learned that on July 23, the Securities Regulatory Commission issued the “Approval to Register the Initial Public Offering of Shares by Suzhou Sinowei Pharmaceutical Technology Co., Ltd.” According to reports, Xinovi plans to be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, and Cathay Pacific Haitong Securities is its sponsor and plans to raise 2.94 billion yuan.

According to the prospectus, Xinovi is an innovative pharmaceutical company that focuses on major unmet clinical needs around the world, is disease-oriented, and is committed to transforming innovation into clinical value and providing patients with the best treatment drugs in the field of diseases. The company has formed a second tier of “1 (NDA) +3 (Phase III) +N” innovative drug pipeline, and has initially achieved innovative feedback research and development through global BD3 licensing or transfer.

The company's first innovative drug, imidexifol for injection, is expected to be approved for domestic marketing in 2026. Three drugs, including XNW5004, XNW27011, and XNW28012, have been recognized as breakthrough therapeutics by the CDE. It is expected to be launched domestically one after another from 2027 to 2028, which can continue to drive the rapid growth of the company's drug sales revenue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.